Relato de caso – eventos neuromusculares relacionados com inibidores de checkpoint

Autores

DOI:

https://doi.org/10.34024/rnc.2022.v30.12780

Palavras-chave:

Miastenia gravis, miopatia, neuropatia, imunoterapia, anti-pd1, melanoma, neoplasia, câncer

Resumo

O melanoma invasivo possui alta mortalidade e sua incidência tem aumentado nos últimos anos de forma considerável. A descoberta dos inibidores de checkpoint (ICP), melhorou significativamente o prognóstico do tratamento, aumentando sobrevida e qualidade de vida dos pacientes com essas neoplasias. Embora a eficácia comprovada desses tratamentos tenha mudado a história natural do melanoma, vários efeitos colaterais foram relatados, principalmente relacionados ao sistema imunológico. O objetivo desse estudo é descrever um caso de eventos neuromusculares sobrepostos de miopatia, miastenia gravis e neuropatia periférica após início de tratamento com anti-PD1 (Nivolumab) em um paciente com melanoma invasivo.

Métricas

Carregando Métricas ...

Downloads

Não há dados estatísticos.

Referências

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet 2018;392:971-84. https://doi.org/10.1016/S0140-6736(18)31559-9

Herrscher H, Robert C. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. Curr Opin Oncol 2020;32:106-13. https://doi.org/10.1097/cco.0000000000000610

Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016;29:806-12.

https://doi.org/10.1097/wco.0000000000000391

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:1721-8. https://doi.org/10.1001/jamaoncol.2018.3923

Kao JC, Brickshawana A, Liewluck T. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors. Curr Neurol Neurosci Rep 2018;18:63. https://doi.org/10.1007/s11910-018-0878-7

Johansen A, Christensen SJ, Scheie D, Højgaard JLS, Kondziella D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review. Neurology 2019;92:663-74. https://doi.org/10.1212/wnl.0000000000007235

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol 2016;2:234-40. https://doi.org/10.1001/jamaoncol.2015.4368

Touat M, Maisonobe T, Knauss S, Hadj B, Salem O, Hervier B, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 2018;91:e985-94. https://doi.org/10.1212/wnl.0000000000006124

Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, et al. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. Circulation 2018;138:743-5. https://doi.org/10.1161/circulationaha.118.035898

Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 2019;48:736-40. https://doi.org/10.1016/j.semarthrit.2018.05.006

Seki M, Uruha A, Ohnuki Y, Kamada S, Noda T, Onda A, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 2019;100:105-13.

https://doi.org/10.1016/j.jaut.2019.03.005

Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 2019;106:12-23. https://doi.org/10.1016/j.ejca.2018.09.033

Makarious D, Horwood K, Coward JIG. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 2017;82:128-36. https://doi.org/10.1016/j.ejca.2017.05.041

Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017;89:1127-34. https://doi.org/10.1212/wnl.0000000000004359

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019;115:854-68. https://doi.org/10.1093/cvr/cvz026

Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol 2019;130:1440-5. https://doi.org/10.1016/j.clinph.2019.03.035

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95. https://doi.org/10.1186/s40425-017-0300-z

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714-68.

https://doi.org/10.1200/jco.2017.77.6385

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw 2019;17:255-89. https://doi.org/10.6004/jnccn.2019.0013

Downloads

Publicado

2022-01-25

Como Citar

Queiroz Borges, M., Camila Rodrigues Dias , E., Augusto de Sousa Neto, Z., Resende Guedes, M., Pereira Prado, Ábner, & Diniz Carneiro, M. A. (2022). Relato de caso – eventos neuromusculares relacionados com inibidores de checkpoint. Revista Neurociências, 30, 1–12. https://doi.org/10.34024/rnc.2022.v30.12780

Edição

Seção

Relato de Caso
Recebido: 2021-10-04
Aceito: 2021-12-07
Publicado: 2022-01-25

Artigos Semelhantes

1 2 3 4 5 > >> 

Você também pode iniciar uma pesquisa avançada por similaridade para este artigo.

Artigos mais lidos pelo mesmo(s) autor(es)